论文部分内容阅读
倍他索洛尔(Betaxolol)是一种脂溶的心脏选择性β受体阻滞剂。受试者为平均年龄52(40～70)岁的15(男14、女1)例慢性稳定型心绞痛患者,试验前停用心脏活性药物3天,硝酸甘油片例外。其中13例左室喷血分数(LVEF)≥50％。首先进行症状限制性立位蹬车试验,运动终点为中度心绞痛2例、呼吸困难7例和过度疲劳6例。运动前(静息)和极量运动时~(99m)Tc-高锝酸盐首次通过法造影,测定LVEF(收缩功能)和左室充盈速率峰值(PFR,舒张功能)等指标。约48小时后口服单剂Betaxolol20mg,
Betaxolol is a fat-soluble cardioselective beta-blocker. Subjects were 15 (14 male and 1 female) chronic stable angina patients, mean age 52 (40-70 years), with cardiac activity discontinued for 3 days prior to the test, with the exception of nitroglycerin tablets. Thirteen of them had left ventricular ejection fraction (LVEF) ≥50%. First of all, the symptom-limited standing pedaling test was carried out. The endpoints of exercise were 2 cases of moderate angina, 7 cases of dyspnea and 6 cases of fatigue. Before exercise (rest) and extreme exercise ~ (99m) Tc-pertechnetate for the first time by contrast angiography, determination of LVEF (systolic function) and left ventricular filling rate peak (PFR, diastolic function) and other indicators. About 48 hours after oral administration of a single dose of Betaxolol 20mg,